We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
National Cancer Research Institute, Japan Uses Nonlinear Dynamics’ SameSpots Technology for its Biomarker Discovery Program
News

National Cancer Research Institute, Japan Uses Nonlinear Dynamics’ SameSpots Technology for its Biomarker Discovery Program

National Cancer Research Institute, Japan Uses Nonlinear Dynamics’ SameSpots Technology for its Biomarker Discovery Program
News

National Cancer Research Institute, Japan Uses Nonlinear Dynamics’ SameSpots Technology for its Biomarker Discovery Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "National Cancer Research Institute, Japan Uses Nonlinear Dynamics’ SameSpots Technology for its Biomarker Discovery Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nonlinear Dynamics Ltd has announced that the National Cancer Research Institute (Tokyo, Japan) is using Progenesis SameSpots as part of its biomarker discovery program.

The National Cancer Research Institute adopted this new technology to support its mission of advancing knowledge in cancer prevention, diagnosis and therapy for cancer control. Progenesis SameSpots offers a major breakthrough in the analysis of 2D single stain and DIGE images, creating new possibilities for 2D based proteomics research.

The new technology has shown its value. Dr. Kondo and his group are identifying biomarker candidates for prediction of response to the chemotherapy (gefitinib, Iressa) in lung adenocarcinoma using Progenesis SameSpots. This is important research because in Japan, while the incidence of stomach cancer is decreasing those of lung, colorectal and breast cancers are increasing.

Dr. Kondo also discovered biomarker candidates for prediction of early metastasis post surgery in gastrointestinal stromal tumor (GIST). Dr. Kondo said, “We will be able to select the patients who are destined to have recurrence and improve their clinical outcome by adjuvant chemotherapy."

Dr. Kondo and his team are developing biomarkers to predict the lymph node metastasis in esophageal cancer, the early recurrence in hepatocellular carcinoma, and the response to neo-adjuvant chemotherapy in osteosarcoma. Prediction performance of the identified biomarkers is extensively validated in a clinical-scale sample set in his laboratory.

The image alignment of SameSpots offers users a streamlined 2D workflow, largely through the elimination post analysis editing. This speeds up the 2D analysis process and reduces the subjectivity which user-operated editing introduces.

Advertisement